Trial Profile
A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Budigalimab (Primary) ; SC 011 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors AbbVie
- 06 Jun 2023 Preliminary results (n=99; at data cutoff date: 22 Aug 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 01 Jun 2023 According to a Sarah Cannon Research Institute media release, data from this trial will be presented in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Patients with Small Cell Lung Cancer, on June 5 at 8 a.m. CDT in Hall D2.
- 15 May 2023 Status changed from recruiting to active, no longer recruiting.